Can liver stiffness changes predict outcomes? 📊 This meta-analysis shows dynamic LSM shifts matter—↑ risk in progressors, ↓ risk in regressors ✅ Serial LSM could help monitor chronic liver disease & guide trials. 🧬 #LiverDisease #Hepatology 🔗: https://ow.ly/6UUl50ZepbB

CGH has received a 2025 Impact Factor of 16.2! On behalf of Editor-in-Chief Charles Kahi, thank you to our editors, authors, reviewers, and readers for your continued support. https://ow.ly/C1J950Zeox2 #GITwitter #LiverTwitter @JosephHabibi_MD @AmerGastroAssn

1 in 3 asymptomatic Barrett’s patients on PPI still show pathological reflux on 24‑hr pH monitoring—linked to neoplasia. 🧪 Esophageal function testing can guide personalized care and may help reduce progression risk. 🎯 🔗: https://ow.ly/i2un50ZbZ66

High cecal intubation rates (CIR) matter! 📊 An Austrian registry study shows lowest PCCRC death risk when endoscopist CIR >95%, outperforming current 90–95% standards—higher is better. ✅ @jzspitzenberg 🔗: https://ow.ly/3pvL50Z8TMo

Using the All of Us database, we found sexual orientation was independently linked to DGBI diagnoses in men, not women. 🧠 Gay & bisexual men had higher odds of IBS, functional diarrhea, and chronic constipation vs. straight men. 📊 🔗: https://ow.ly/ySYV50Z8TFb

This large, real-world study of Veterans with IBD using quasi-experimental study designs, vitamin D supplementation was associated with reduced emergency department visits (34% RRR), hospitalizations (53% RRR), and corticosteroid prescriptions (25% RRR). 🔗https://ow.ly/A3Ar50Z8T4X

📌Metabolic dysfunction drives MASLD risk in children. In a 4-year study, persistent or new metabolic issues increased hepatic steatosis risk—but resolution removed excess risk. Early intervention is key for improving pediatric liver health. 🔗: https://ow.ly/z6xf50Z4Pwq

🌟Noninvasive scores (SAVE, ABC, LSPS, CHESS-ALARM) better predict decompensation in compensated advanced chronic liver disease than fibrosis models (MELD, ALBI, VITRO, FIB‑4) in practice. 🔗: https://ow.ly/byff50Z4NxC

📖 The June issue of #CGH is now online! It features: 🟣 A study on the effect of CIR on Post Colonoscopy Colorectal Cancer Deaths 🟣 Research on Psychomotor Development in Infants 🟣 A 10-Year Retrospective Multicenter Survey on 997 Patients in China 🔗: https://ow.ly/QRjE50Z4NhH

Adults diagnosed with #CeliacDisease with impaired work ability face higher health care costs—not just at diagnosis, but years later, often from non‑celiac causes. New research calls for personalized, multidisciplinary care. 🔗: https://ow.ly/otYV50Z2cMe#CeliacDisease #CeliacAwarenessMonth

Text message 📱 and mailed reminders ✉️ significantly boosted responses to mailed FIT in a randomized trial—but a branded box didn’t move the needle. 📦❌ @PM_Innovation @PennMedicine 🔗: https://ow.ly/9u1z50YVzF2

📊👧 When should children be screened for #CeliacDisease? New cost-effectiveness modeling suggests a one-time screening around age 11 may be most efficient—and repeated screening may work best at ages 4 and 11. 🔗: https://ow.ly/EfSV50YYr3w#CeliacDisease? #CeliacAwarenessMonth

🌐In this nationwide cohort from Sweden, both histologic inflammation (vs. histologic remission) and clinically active IBD (vs. quiescent IBD) were associated with an increased 2-year mortality risk in patients with IBD. @jiangwei_sun; @ludvigsson 🔗: https://ow.ly/QijX50YVzgj

People with MASLD and advanced fibrosis have a substantial risk of hepatocellular carcinoma in this IPD meta-analysis. Findings may inform future risk‑stratification strategies. 🧬📊 @DrHuangDQ @LimRyan21 🔗: https://ow.ly/rZKm50YVyPI

🚨Placebo response rates are often high in patients with MASH, but vary by the outcome measured. This study offers critical insights to improve future clinical trial design. 🔗: https://ow.ly/MymC50YVyEu

Happening soon! Join us at AGA Central for You’ve Published Your Paper… Now What? and learn strategies for promoting your work from our @AGA_GHA & @AGA_CGH social media editors Nikki Duong MD and Joseph Sleiman, MD #DDW2026 📅 5/4 | ⏰ 2 PM CT | 📍 AGA Central

Join us bright and early at AGA Central for our One Paper, Zero Confusion session — get tips on getting your title and graphical abstract just right from @AGA_CMGH editors-in-chief Michele Battle & Jonathan Katz! #DDW2026 📅 5/4 | ⏰ 8 AM CT | 📍 AGA Central

Happening today! Don’t miss our From Poster to Submission session at AGA Central with the editors-in-chief of @AGA_Gastro, @AGA_CGH, and @AGA_CMGH! #DDW2026 📅 5/2 | ⏰ 1 PM CT | 📍 AGA Central

Already published at #DDW2026? Join us at AGA Central for You’ve Published Your Paper… Now What? and learn what comes next. Featuring our @AGA_GHA & @AGA_CGH social media editors Nikki Duong MD and Joseph Sleiman, MD#DDW2026? 📅 5/4 | ⏰ 2 PM CT | 📍 AGA Central

Mapping out your #DDW2026 schedule? Join us at AGA Central for One Paper, Zero Confusion—tips on getting your title and graphical abstract just right with @AGA_CMGH editors-in-chief Michele Battle & Jonathan Katz! 📅 5/4 | ⏰ 8 AM CT | 📍 AGA Central

Attending #DDW2026? Stop by AGA Central for our From Poster to Submission session! Featuring editors-in-chief of @AGA_Gastro, @AGA_CGH, and @AGA_CMGH. 📅 5/2 | ⏰ 1 PM CT | 📍 AGA Central

📖 In case you missed it, the May 2026 issue of CGH is out! Featured topics ⬇️ 🟢 Esophageal inflammatory diseases 🟢 Extended risankizumab treatment in UC 🟢 CRC screening interventions ➡️ Full issue: https://ow.ly/9shw50YRMt5

There's still time! The AGA Journals are accepting applications for a one-year editorial fellowship focused on editorial training and leadership development. ⭐Perfect for early-career GIs and PhDs ✅Applications due April 30, 11:50 p.m. EST 👩‍⚕️Learn more: https://ow.ly/u7Gq50YOFoY

💊GLP-1 drugs like Ozempic and Wegovy have far-reaching health benefits beyond weight loss. In a new nationwide cohort study, researchers from Beth Israel Deaconess Medical Center are adding one more to that list: prevention of ulcers in the gut. 🔗: https://ow.ly/u2Oa50YO61B

🌟This international, multicenter study identified both commonalities and unique differences in disease phenotype and behavior by geography and immigrant status, highlighting the impact of changing environment on CD phenotypic expression. 🔗: https://ow.ly/A8uK50YLl9u

Subcutaneous infliximab (infliximab‑dyyb SC) maintenance improved outcomes in Crohn’s disease regardless of location, showing consistent efficacy across ileocolonic segments—including the terminal ileum. 💉✨ 🔗: https://ow.ly/PuPX50YFESt

🥗 Do dietary emulsifiers affect gut health? In a randomized trial, an emulsifier‑free diet lowered cholesterol, while common emulsifiers reduced short‑chain fatty acids and increased gut permeability in some participants. 🧫🦠 🔗: https://ow.ly/pVeC50YFEq4

📈 DGBI prevalence and burden increased in the UK & US after COVID-19. Key factors include repeat infections, abdominal pain/diarrhea during infection, and long COVID. 🦠🧠 🔗: https://ow.ly/gQCL50YFE4t

💊GLP-1 drugs like Ozempic and Wegovy have far-reaching health benefits beyond weight loss. In a new nationwide cohort study, researchers from Beth Israel Deaconess Medical Center are adding one more to that list: Prevention of ulcers in the gut! 🔗: https://ow.ly/FSJ450YBJUt

🧪 Plastic exposure is unavoidable. As plastics break down into micro‑ and nanoplastics, they spread through water, soil, and air—and when ingested, may disrupt gut microbes and mucosal barriers, driving inflammatory and carcinogenic effects. ⚠️🦠 🔗: https://ow.ly/xrHv50YBJuM

📊 New multicenter data show peripancreatic vascular involvement is common in autoimmune pancreatitis—and highly responsive to glucocorticoids. Monitoring can help prevent life‑threatening gastric varices. 💊🩸 🔗: https://ow.ly/tfp050YBJiH

📊 Real‑world TORUS study: after anti‑TNF failure in UC, tofacitinib and ustekinumab showed similar effectiveness. Tofacitinib may be favored after multiple biologic failures or primary biologic nonresponse. 🔍✅ Read More: https://ow.ly/Fhfc50YyRGx

🧪 In this Phase 2a study in Asian patients with MASLD: the THR‑β agonist HSK31679 significantly reduced liver fat content after 12 weeks—greatest with 80 mg and 160 mg. ✅ The treatment was well tolerated, with no AE‑related discontinuations. Read More: https://ow.ly/LBj550YyRpx

🧬 Who should be treated for MASLD? This Hepatology original research article explores a practical criteria set—combining FIB‑4, transient elastography, diabetes, and overweight status—to better guide treatment decisions. 📖✨ Read More: https://ow.ly/Khfe50YyR2o

🌍 April 2026 Editors Essential Reading 📘 This Global NASH/MASH Council study projects that by 2040, the clinical, economic, and humanistic burden of MASH will more than double worldwide—underscoring the urgent need for action. 🚨 Read More: https://ow.ly/f8yR50YyQrU

🗣️ The newest issue of CGH is here!! ➡️ https://ow.ly/6AbI50Yy7w6

📌 First meta-analysis on recompensation in decompensated cirrhosis 🔍 More common in viral etiologies & lower MELD 📉 Linked to lower risk of HCC & death ✅ A meaningful clinical endpoint Read more here: https://ow.ly/tYnJ50YvNUo #LiverTwitter @wong__yujun @BavenoCoop

🌟A survey of 54,127 participants from 26 countries identified four dietary clusters associated with global IBS prevalence and severity. The findings highlight regional dietary patterns and their association with IBS. @DipeshVasant 🔗: https://ow.ly/6qOf50YvMM0

📱 Can digital health expand #CRC screening? In the BLITZ study, a smartphone‑based FIT showed feasible use and diagnostic performance comparable to lab FITs for advanced neoplasms, supporting it as an adjunct screening option. #CRCAwarenessMonth 🔗: https://ow.ly/HX6E50YvoBt#CRC#CRCAwarenessMonth

🗣️In a survey of 54,127 participants across 26 countries, four dietary clusters linked to global #IBS prevalence and severity were identified. These findings highlight international dietary patterns and their association with IBS. @DipeshVasant 🔗: https://ow.ly/XzPe50YpHsY

📣 Calling all early-career GIs and PhDs! The AGA Journals are now accepting applications for a one-year editorial fellowship program focused on editorial training and leadership development. ⏰ Apply by 04/30/2026 🔗 Details and application: https://ow.ly/fmRZ50YrtyR

🚨#qFibrosis shows 89.2% repeatability (κ=0.88) and 86.5% reproducibility (κ=0.85) in liver fibrosis scoring, matching human pathologist agreement. The AI platform addresses variability in MASH trials, enabling standardized histological assessment. 🔗:https://ow.ly/miua50YpGRV

📱 Can digital health expand #CRC screening? In this BLITZ study, a smartphone‑based FIT showed feasible use and diagnostic performance comparable to lab FITs for advanced neoplasms, supporting it as an adjunct screening option. #CRCAwarenessMonth 🔗: https://ow.ly/siEs50YqpuP#CRC

🌟Which therapies improve survival in severe alcohol‑associated hepatitis? A new systematic review highlights corticosteroids as first‑line treatment and evaluates emerging combination strategies. 🔗: https://ow.ly/kuog50YpGJq

✴️The March issue of #CGH is now online! This issue includes: 🔸A study on the effect of weight loss on patients with Gastrointestinal & Liver Disease 🔸A review on wearable technologies in #IBD 🔸Research on neoplasia detection rates 🔸...And more! 🔗: https://ow.ly/HeGe50Ym6VX#CGH#IBD

🌟CVE provides a means for automated ulceration and mucosal injury quantitation that shows conceptual agreement with SES-CD. CVE offers new capabilities to improve the granularity and personalization of endoscopic disease assessment in CD. 🔗: https://ow.ly/kmpw50YhhoM

A growing body of evidence suggests microplastics & nanoplastics may affect GI and liver health. A comprehensive @AGA_CGH review found microplastics linked with inflammation, gut dysbiosis, liver disease and possibly GI cancers ➡️ https://ow.ly/j41w50YhkmU @dutta_priyata @AGA_GIHN

‼️New data show acne is a common and impactful side effect of JAK inhibitors in IBD—highlighting the need for early recognition and proactive management. 🔗: https://ow.ly/szta50YhgEN @Sash_Honap @PeyrinBiroulet @ibdseb @eathar_s @shahidadin1 @TakuKobayashiM1 P7278 @PolychronisP

🧬“Distal eosinophilia predicts PPI response in EoE, while proximal‑predominant patterns predict nonresponse. Distribution may reflect distinct phenotypes and guide care.” @walterchanmd @mayssanmuftah 🔗: https://ow.ly/tHtp50Y8M0J

🗣️"Patients with both adenomas and significant serrated polyps face a higher risk of advanced neoplasia than those with either alone. They may benefit from shorter colonoscopy surveillance intervals than current guidelines recommend." 🔗: https://ow.ly/UMmf50Y8Lig